KR20210047313A - Smarca2/brm atp분해효소 저해제로서의 우레아 화합물 및 조성물 - Google Patents

Smarca2/brm atp분해효소 저해제로서의 우레아 화합물 및 조성물 Download PDF

Info

Publication number
KR20210047313A
KR20210047313A KR1020217007586A KR20217007586A KR20210047313A KR 20210047313 A KR20210047313 A KR 20210047313A KR 1020217007586 A KR1020217007586 A KR 1020217007586A KR 20217007586 A KR20217007586 A KR 20217007586A KR 20210047313 A KR20210047313 A KR 20210047313A
Authority
KR
South Korea
Prior art keywords
cancer
carcinoma
leu
brm
brg1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217007586A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 아데어
줄리엔 파필론
카츠마사 나카지마
트로이 더글라스 스미스
루쿤도 은타간다
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20210047313A publication Critical patent/KR20210047313A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217007586A 2018-08-17 2019-08-12 Smarca2/brm atp분해효소 저해제로서의 우레아 화합물 및 조성물 Pending KR20210047313A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765138P 2018-08-17 2018-08-17
US62/765,138 2018-08-17
PCT/IB2019/056847 WO2020035779A1 (en) 2018-08-17 2019-08-12 Urea compounds and compositions as smarca2/brm atpase inhibitors

Publications (1)

Publication Number Publication Date
KR20210047313A true KR20210047313A (ko) 2021-04-29

Family

ID=68072895

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217007586A Pending KR20210047313A (ko) 2018-08-17 2019-08-12 Smarca2/brm atp분해효소 저해제로서의 우레아 화합물 및 조성물

Country Status (21)

Country Link
US (2) US11958846B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219488A1 (cg-RX-API-DMAC7.html)
JP (1) JP7328323B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210047313A (cg-RX-API-DMAC7.html)
CN (2) CN112585136B (cg-RX-API-DMAC7.html)
AU (1) AU2019322325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107097A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126039T1 (cg-RX-API-DMAC7.html)
DK (1) DK3837256T3 (cg-RX-API-DMAC7.html)
ES (1) ES2946060T3 (cg-RX-API-DMAC7.html)
FI (1) FI3837256T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230477T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061963T2 (cg-RX-API-DMAC7.html)
LT (1) LT3837256T (cg-RX-API-DMAC7.html)
MX (1) MX2021001804A (cg-RX-API-DMAC7.html)
PL (1) PL3837256T3 (cg-RX-API-DMAC7.html)
PT (1) PT3837256T (cg-RX-API-DMAC7.html)
RS (1) RS64238B1 (cg-RX-API-DMAC7.html)
SI (1) SI3837256T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020035779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN112585136B (zh) 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
EP4734993A2 (en) * 2023-06-30 2026-05-06 Dana-Farber Cancer Institute, Inc. Methods for sensitizing drug-resistant cancer cells

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US2871243A (en) * 1956-10-26 1959-01-27 May & Baker Ltd 5-amino-3-methyl-isothiazole and process
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
GB9823873D0 (en) * 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US7304066B2 (en) 2001-05-24 2007-12-04 Bjoerkling Fredrik Pyridyl cyanoguanidine compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
CN103463084A (zh) 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
CN103880737A (zh) * 2014-02-27 2014-06-25 浙江泰达作物科技有限公司 1-(2-氯-4-吡啶基)-3-苯基脲的制备方法
DK3169671T3 (da) 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CN105481723B (zh) 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
WO2018187414A1 (en) 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions
CN112585136B (zh) * 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
WO2020126968A2 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Also Published As

Publication number Publication date
US20240270738A1 (en) 2024-08-15
PL3837256T3 (pl) 2023-07-10
FI3837256T3 (fi) 2023-05-15
CN118666832A (zh) 2024-09-20
JP7328323B2 (ja) 2023-08-16
US20210323956A1 (en) 2021-10-21
AU2019322325B2 (en) 2022-01-20
EP3837256A1 (en) 2021-06-23
JP2021534147A (ja) 2021-12-09
HRP20230477T1 (hr) 2023-07-21
RS64238B1 (sr) 2023-06-30
SI3837256T1 (sl) 2023-07-31
AU2019322325A1 (en) 2021-02-18
CN112585136A (zh) 2021-03-30
CN112585136B (zh) 2024-06-25
LT3837256T (lt) 2023-06-12
EP4219488A1 (en) 2023-08-02
DK3837256T3 (da) 2023-05-30
ES2946060T3 (es) 2023-07-12
HUE061963T2 (hu) 2023-09-28
WO2020035779A1 (en) 2020-02-20
BR112021002632A2 (pt) 2021-05-11
US11958846B2 (en) 2024-04-16
PT3837256T (pt) 2023-05-23
EP3837256B1 (en) 2023-03-08
CA3107097A1 (en) 2020-02-20
CY1126039T1 (el) 2023-11-15
MX2021001804A (es) 2021-04-19
US12358906B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
AU2019322325B2 (en) Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors
JP7560546B2 (ja) Shp2ホスファターゼ阻害剤並びにその作製方法及び使用方法
JP7856818B2 (ja) クローディン6二重特異性抗体
CN111565744B (zh) 紧密连接蛋白6抗体和治疗癌症的方法
JP2023033414A (ja) Mdm2阻害剤及び1つ以上の追加の医薬活性剤を含む癌治療のための併用療法
EP3341379B1 (en) Inhibitors of ezh2
KR20210068473A (ko) Shp2 활성 억제용 화합물의 제조 방법
KR20070034487A (ko) 항il-13 항체, 항il-13 항체의 결정 및 이를 함유하는복합체
CA3056754A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
CN110248937A (zh) 4,5-环状1,2,4-三唑酮
KR20170076775A (ko) T 세포가 아닌 종양을 표적화하는 서바이빈 특이적인 t-세포 수용체
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
RU2798462C2 (ru) Соединения на основе мочевины и композиции на их основе в качестве ингибиторов атфазы smarca2/brm
CN110461323A (zh) 溶瘤病毒的增殖方法和抗肿瘤剂
Kumar et al. Genomic organization and characterization of the promoter region of murine GSTM2 gene
WO2024035830A1 (en) Solid forms of a cdk inhibitor
US20250042918A1 (en) Compounds
HK40045602B (en) Urea compounds and compositions as smarca2/brm-atpase inhibitors
HK40045602A (en) Urea compounds and compositions as smarca2/brm-atpase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210312

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220801

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240902

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250515